We describe a nonpeptide mimetic analog of an invertebrate peptide receptor 
SchistoFLRFamide (PDVDHVFLRFamide) is a member of a subfamily of insect FMRFamide-related peptides that share the sequence X1DVX4HX6FLRFamide (where X1 is pQ, P, or T; X4 is D or V; and X6 is V or S) and have been identified in such diverse insect species as the cockroach Leucophaea maderae, locusts Locusta migratoria and Schistocerca gregaria, fleshfly Neobelleria bullata, fruitfly Drosophila melanogaster, and the tobacco hornworm Manduca sexta (1, 2) . Members of this subfamily have actions on insect muscle, being potent inhibitors (myosuppressins) of cardiac and visceral muscle, in addition to having effects on skeletal muscle, longitudinal flight muscles, and salivary glands (2, 3) . SchistoFLRFamide (4), isolated from locusts, is associated with their oviducts, where it inhibits spontaneous contractions and contractions induced by high-potassium saline, neural stimulation, and the pentapeptide proctolin (RYPLT) (5) . Leucomyosuppressin or LMS (pQDVDHVFLRFamide), isolated from the cockroach Leucophaea maderae, is inhibitory on cockroach hindgut, oviduct, and heart spontaneous contractions and also inhibits evoked transmitter release at the neuromuscular junction of the mealworm Tenebrio molitor (6, 7) . Structure-activity studies using truncated forms of both SchistoFLRFamide and LMS have revealed that the active core for SchistoFLRFamide lies in the sequence HVFLRFamide (which has similar potency to the parent compound) (1), whereas the active core for LMS lies in the sequence VFLRFamide, although DHVFLRFamide is markedly more potent (3) .
Recently, it was observed that the nonpeptide benzethonium chloride (Bztc) shares several chemical features with the sequence VFLRFamide (8) . As can be seen in Fig. 1 Interestingly, it was found that Bztc mimicked the physiological effect of LMS on both cockroach hindgut and mealworm neuromuscular junction (7, 8) . Thus, Bztc reversibly inhibited spontaneous contractions of hindgut at a threshold of 6 x 10-8 M, essentially equivalent in potency to the myosuppressin C-terminal pentapeptide core. Bztc reversibly suppressed evoked excitatory postsynaptic potentials at mealworm neuromuscular junctions, with 50% inhibition induced by 10-4 M.
As with LMS, both the suppression of mealworm neuromuscular junction excitatory postsynaptic potentials and inhibition of cockroach hindgut contraction evoked by Bztc were blocked by nordihydroguiaretic acid, an inhibitor of lipoxygenase (8 In the present study we have used the locust oviduct bioassay and binding assay to examine more closely the possibility that Bztc may be a ligand of the myosuppressin receptors.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. [Y1]SchistoFLRFamide (YDVDHVFLRFamide) was radioiodinated by a typical chloramine-T method as described (9) . The plasma membranes of locust oviducts were prepared as described (9) . Briefly, the oviducts from 28-day-old adult female locusts were dissected out and homogenized by using a Potter-type glass homogenizer in ice-cold extraction buffer (150 mM NaCl/4 mM CaCl2/2 mM MgCl2/10 mM KCl/4 mM NaHCO3/5 mM Hepes, pH 7.2/1 mM phenylmethylsulfonyl fluoride/i mM 2-mercaptoethanol; 4 ml of buffer per g of tissue). The homogenate was centrifuged at 800 x g for 10 min at 4°C to remove cell debris, and the resulting supernatant was centrifuged at 30,000 x g for 1 h to collect plasma membranes. The pellet was washed with the same buffer. Finally, the pellet was resuspended in the extraction buffer and adjusted to a concentration of 10 ,ug of protein per ,ul. Total protein was determined by the Bio-Rad assay with y-globulin as the protein standard.
Receptor Binding Assay. Binding assays were carried out as described (9) . Briefly, 100 ,ug of membrane preparation was 
RESULTS AND DISCUSSION
Initially, we assessed the physiological effects of Bztc on locust oviduct. Fig. 2 shows that Bztc can mimic the effects of SchistoFLRFamide in being able to reversibly inhibit proctolin-induced contractions of locust oviduct. The dose-response curve for Bztc shows a shift to the right with the threshold for Bztc being higher than for SchistoFLRFamide (5 x 10-7 M vs. 10-9 M, respectively) and the concentration causing 50% inhibition of the proctolin-induced contraction also higher for Bztc (6 x 10-5 M vs. 2 X 10-7 M). Similarly, Bztc reversibly inhibits neurally evoked contractions of locust oviduct (Fig. 3) , but once again threshold is higher than for SchistoFLRFamide and the concentration for 50% inhibition is higher (3 x 10-5 M for Bztc vs. 10-8 M for SchistoFLRFamide). Bztc is also able to inhibit spontaneous contractions of locust oviduct, as it does in cockroach hindgut, and lower basal tonus (Fig. 3A) . Thus, with regard to biological activity, the nonpeptide Bztc is able to mimic the peptide SchistoFLRFamide on locust oviduct. By using binding studies that give a direct assessment of an interaction on receptors, we found that Bztc competitively displaced [1251-labeled Y1]SchistoFLRFamide from both highand low-affinity receptors (Fig. 4) . Binding to both high-and low-affinity receptors is competitively displaced by [Y1]SchistoFLRFamide with K1 values of 6.9 x 10-10 M and 5.0 X 10-7 M, respectively. Bztc also competitively displaces the A radioligand, although as with biological activity, higher doses are required and the displacement curve is shifted to the right. The Ki for Bztc is 6.3 x 1o-8 M for the high-affinity site and 1.5 X 10-4 M for the low-affinity site. For comparative purposes, the displacement curve for Bztc is similar to that of FLRFamide, which has a Ki of 5.1 x 10-8 M for the highaffinity site and a Ki of 8.5 x 10-6 M for the low-affinity site (10) .
The data provide clear evidence from both biological activity and displacement from binding sites that the nonpeptide Bztc is recognized by SchistoFLRFamide receptors, and, thus, Bztc is a nonpeptide ligand for a peptide receptor in invertebrates. In the vertebrates, especially mammals, nonpeptide ligands have been described for the cholecystokinin system (11), substance P (12), and vasopressin (13) .
The discovery of nonpeptide ligands is an important lead. Substances that mimic or block the action of endogenous peptides are useful for defining the physiological functions of these peptides. However, they also have considerable potential for insect pest management. Peptides control a vast array of physiological activities in insects. For instance, this subfamily of FMRFamides, the myosuppressins, controls muscular activity associated with locomotion, reproduction, and digestion, and disruption of these activities would have damaging con- sequences to the insect (14) . However, the use of peptides per se as pesticides would appear impractical since their chemistry would make them susceptible to degradation under field conditions and to digestion after feeding, and their polarity would make uptake through the cuticle difficult (8, 14) . Over the last few years, some progress has been made in the development of stable peptide analogues. In several of these examples, some amino acids have been modified or replaced giving the structure a degree of pseudopeptide or nonpeptide character (8, 15, 16) . However, problems of degradation, transport, and excretion still remain to be resolved. Totally nonpeptide compounds overcome many of these problems and also allow leads for the synthesis of a series of related analogues and/or screening of chemical data banks for similar structures. Due to resistance to peptidase degradation, nonpeptide mimetic analogs need not be as potent as the endogenous peptides to disrupt physiological processes and/or normal behavioral patterns of insects. Thus, it is worth reiterating that the importance of neuropeptides as potential leads for pest control is not the molecule as such but the information encoded within it (14, 15) . The identification of the nonpeptide Bztc that must match some of the binding and activation structures encoded within SchistoFLRFamide provides a unique opportunity within insects to finally target a peptide receptor for the development of future pest management strategies.
